CONMED (CNMD) Worth up to $59/Share in Takeover - Needham & Company

April 16, 2014 8:14 AM EDT
Get Alerts CNMD Hot Sheet
Price: $43.63 --0%

Rating Summary:
    4 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 28 | Down: 28 | New: 23
Trade CNMD Now!
Join SI Premium – FREE

Needham & Company analyst Mike Matson weighed in on CONMED (NASDAQ: CNMD) amid reports Tuesday the company hired advisers to help with a possible sale of the company

Maston said, "With two activist firms targeting CNMD, we are not too surprised by this news. We believe that CNMD could be worth $59 per share in a potential acquisition and that a deal could prove accretive to a larger medical device company. While there is clearly a risk that CNMD will not be acquired, we believe that fundamentals are improving and that shares are attractive even absent a deal. "

With the Reuters article that the company's bankers are approaching the larger orthopedics companies, the analyst highligted Covidien (NYSE: COV), Johnson & Johnson (NYSE: JNJ), Medtronic (NYSE: MDT), Stryker (NYSE: SYK), and Zimmer (NYSE: ZMH) as logical potential acquirors of CNMD. Aside from these companies, they think that larger European or Asian medical device companies might also be interested in CNMD.

The firm maintained a Buy rating and price target of $54 on CNMD.

For an analyst ratings summary and ratings history on CONMED click here. For more ratings news on CONMED click here.

Shares of CONMED closed at $45.25 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Rumors

Related Entities

Needham & Company, Definitive Agreement

Add Your Comment